Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Fulda

Showing results (71-80 of 287) with videos related to

Pageof 29
Sort By:
Cancer Research|January 20, 2004
Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrolSimone Fulda, Klaus-Michael Debatin
Archivum Immunologiae Et Therapiae Experimentalis|May 3, 2006
Modulation of apoptosis signaling for cancer therapySimone Fulda, Klaus-Michael Debatin
Vitamins and Hormones|April 28, 2004
Modulation of TRAIL signaling for cancer therapySimone Fulda, Klaus-Michael Debatin
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signallingSimone Fulda, Klaus-Michael Debatin
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Death receptor signaling in cancer therapySimone Fulda, Klaus-Michael Debatin
Neoplasia (New York, N.Y.)|April 2, 2005
Sensitization for anticancer drug-induced apoptosis by betulinic AcidSimone Fulda, Klaus-Michael Debatin
Cell Cycle (Georgetown, Tex.)|April 4, 2007
HIF-1-regulated glucose metabolism: a key to apoptosis resistance?Simone Fulda, Klaus-Michael Debatin
Cancer Letters|July 26, 2003
Apoptosis pathways in neuroblastoma therapySimone Fulda, Klaus Michael Debatin
Current Opinion in Pharmacology|July 15, 2004
Signaling through death receptors in cancer therapySimone Fulda, Klaus-Michael Debatin
Cancer Biology & Therapy|October 14, 2005
HDAC inhibitors: double edge sword for TRAIL cancer therapy?Simone Fulda, Klaus-Michael Debatin
Pageof 29

Showing results (71-80 of 287) with videos related to

Sort By:
Pageof 29
Cancer Research|January 20, 2004
Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrolSimone Fulda, Klaus-Michael Debatin
Archivum Immunologiae Et Therapiae Experimentalis|May 3, 2006
Modulation of apoptosis signaling for cancer therapySimone Fulda, Klaus-Michael Debatin
Vitamins and Hormones|April 28, 2004
Modulation of TRAIL signaling for cancer therapySimone Fulda, Klaus-Michael Debatin
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signallingSimone Fulda, Klaus-Michael Debatin
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Death receptor signaling in cancer therapySimone Fulda, Klaus-Michael Debatin
Neoplasia (New York, N.Y.)|April 2, 2005
Sensitization for anticancer drug-induced apoptosis by betulinic AcidSimone Fulda, Klaus-Michael Debatin
Cell Cycle (Georgetown, Tex.)|April 4, 2007
HIF-1-regulated glucose metabolism: a key to apoptosis resistance?Simone Fulda, Klaus-Michael Debatin
Cancer Letters|July 26, 2003
Apoptosis pathways in neuroblastoma therapySimone Fulda, Klaus Michael Debatin
Current Opinion in Pharmacology|July 15, 2004
Signaling through death receptors in cancer therapySimone Fulda, Klaus-Michael Debatin
Cancer Biology & Therapy|October 14, 2005
HDAC inhibitors: double edge sword for TRAIL cancer therapy?Simone Fulda, Klaus-Michael Debatin
Pageof 29